Inclisiran sodium is a novel small interfering RNA (siRNA) therapeutic developed by Alnylam Pharmaceuticals and commercialized by Novartis.

Numab Therapeutics has begun a Phase 1 clinical trial for the NM32 program targeting patients with solid tumors.

Empagliflozin is a medication used primarily to treat type 2 diabetes and, in some cases, to help manage heart failure.

ProMIS Neurosciences Shares Encouraging Results from Phase 1a Trial of PMN310 at the 17th Alzheimer’s Disease Clinical Trials Conference.

Cemdisiran, a groundbreaking therapeutic agent, is a small interfering RNA (siRNA) developed by Alnylam Pharmaceuticals in collaboration with Sanofi.

Biomea Fusion has released preclinical findings indicating that Icovamenib (BMF-219) improves the efficacy of GLP-1 therapies.

When discussing pan-KRAS inhibitors, it’s essential to mention RMC-6236, developed by Revolution Medicines.

Kither Biotech has revealed the start of a Phase 1 clinical trial for KIT2014, an innovative inhaled peptide treatment for cystic fibrosis.

latest updates in the global new drug development field, including progress in new drug research and development.

Avidity Biosciences begins a biomarker group in the FORTITUDE™ trial to seek potential fast-track approval for Delpacibart Braxlosiran (del-brax/AOC 1020).

10.28-11.3, Global Pharmaceutical Investment, Financing and Deal Events Summary.

Akeso has initiated patient recruitment for a Phase 3 study assessing Ivonescimab alongside Ligufalimab (CD47) as a first-line therapy for HNSCC.